Categories Earnings, Retail

Kroger (NYSE: KR): Q3 2019 Earnings Snapshot

— The Kroger Co. (NYSE: KR) reported its third-quarter 2019 adjusted earnings of $0.47 per share versus $0.49 per share expected.

— Net sales rose by 0.7% to $28 billion versus $28.18 billion expected. Excluding fuel and dispositions, sales grew 2.7%. Identical Sales without fuel grew 2.5% and digital sales grew 21%.

Kroger (KR) Q3 2019 Earnings Snapshot

— The FIFO gross margin rate, excluding fuel, a decrease of 24 basis points was primarily driven by industry-wide lower gross margin rates in pharmacy and continued growth in the specialty pharmacy business.

— Looking ahead into fiscal 2019, the company lowered its GAAP EPS guidance to the range of $2.17-2.27 from the previous range of $2.30-2.40.

— Adjusted EPS is still expected to be in the range of $2.15-2.25 for fiscal 2019. This is compared to the consensus estimates of $2.20.

— Operating profit outlook is lowered to the range of $2.4-2.5 billion from the prior range of $2.8-2.9 billion while adjusted operating profit is still predicted to be $2.9-3 billion for the full year.

— Capital expenditures are still anticipated to be in the range of $3-3.2 billion for fiscal 2019.

— For fiscal 2020, the company predicts an adjusted EPS of $2.30-2.40. This is compared to the consensus estimates of $2.33.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Comments

  1. Pingback: madridbet
  2. Pingback: ivermectin virus
  3. Pingback: iver mectin
  4. Pingback: stromectol canada
  5. Pingback: child porn
  6. Pingback: buy ivermectin
  7. Pingback: ivermectin 1
  8. Pingback: bahis siteleri
  9. Pingback: 2matthew
  10. Pingback: ivermectin 10 mg
  11. Pingback: grandpashabet
  12. Pingback: sikiş
  13. Pingback: madridbet
  14. Pingback: porn
  15. Pingback: meritking giriş
  16. Pingback: meritking
  17. Pingback: child porn
  18. Pingback: grandpashabet
  19. Pingback: meritking
  20. Pingback: izmir escort
  21. Pingback: fuck google
  22. Pingback: child porn
  23. Pingback: fuck google
  24. Pingback: porn
  25. Pingback: porn
  26. Pingback: sex
  27. Pingback: porn
  28. Pingback: çeşme transfer
  29. Pingback: hd porno izle
  30. Pingback: izmir travesti
  31. Pingback: sikiş
  32. Pingback: yasam ayavefe
  33. Pingback: grandpashabet
  34. Pingback: grandpashabet
  35. Pingback: grandpashabet
  36. Pingback: child porn
  37. Pingback: cratosroyalbet
  38. Pingback: ankara psikolog
  39. Pingback: child porn
  40. Pingback: child porn
  41. Pingback: meritking giriş
  42. Pingback: meritking gir
  43. Pingback: meritking news
  44. Pingback: silivri avukat
  45. Pingback: hp servis izmir
  46. Pingback: fuck
  47. Pingback: grandpashabet
  48. Pingback: porn
  49. Pingback: grandpashabet

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top